Aryl hydrocarbon receptor activation by imidacloprid as a promoter of HER2(+) breast cancer progression: In silico, in vitro and in vivo studies
Environmental Research · 2026
DOI: 10.1016/j.envres.2026.125482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Research, 2026. Verfasst von Sol Buján und 11 weiteren Autor:innen. Beteiligte Einrichtung: CONICET-Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas (INBIOMED), Laboratorio de Efectos Biológicos de Contaminantes Ambiental…. Hauptthemen laut MEDLINE: Nitro Compounds, Receptors, Aryl Hydrocarbon, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 67 Literaturangaben. Gefördert von: Fund for Scientific and Technological Research, Universidad de Buenos Aires, Secretaria de Ciencia y Tecnica, Universidad de Buenos Aires.
Abstract (Originalsprache)
Breast cancer is the most common type of neoplasm in women globally. Growing evidence shows that people living in agricultural areas with heavy pesticide exposure have a higher risk of breast cancer. Imidacloprid (IMI) is a neonicotinoid insecticide used in large-scale agricultural systems, homes, and veterinary pharmaceutical products. The aryl hydrocarbon receptor (AhR) has been linked to breast cancer, and some pesticides can activate its signaling pathways. The G protein-coupled estrogen receptor (GPER) plays a fundamental role in epithelial-mesenchymal transition, relevant to the development of metastasis. In this work, we study IMI effects on human epidermal growth factor receptor 2-positive [HER2(+)] LM3 breast cancer cells, in a syngeneic model of breast tumors in mice, and in in silico analyses of the agonist/antagonist action of IMI on AhR. In LM3 cells, IMI promoted viability, proliferation and migration through AhR and GPER, and increased MMP-2 and MMP-9 activity. In the mouse model, IMI increased tumor growth and lung metastasis. In addition, IMI exposure significantly upregulated AhR protein expression and its canonical target gene cytochrome P450 1A1 mRNA in both models. Moreover, IMI enhanced GPER expression and the activation of ERK. The in silico results show that IMI occupies the AhR ligand-binding pocket with a considerably lower affinity than the full agonist TCDD. Our findings indicate that exposure to IMI promotes tumor growth and progression in a HER2(+) mouse model of breast cancer. Some of its effects can be explained by the insecticide's agonist activity on AhR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CONICET-Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas (INBIOMED), Laboratorio de Efectos Biológicos de Contaminantes Ambientales, Paraguay 2155, 5to piso, Ciudad Autónoma de Buenos Aires, CP1121,…
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica. Departamento de Química Medicinal, Junín 956, Ciudad Autónoma de Buenos Aires, CP1113, Argentina. Electronic address: dimaciodimacio@gmail.com.
- CONICET-Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas (INBIOMED), Laboratorio de Inmunoterapia Antitumoral, Paraguay 2155, 10mo piso, Ciudad Autónoma de Buenos Aires, CP1121, Argentina. Electronic…
- CONICET- Universidad de Buenos Aires, Instituto de Biología Celular y Neurociencias "Prof E. De Robertis" (IBCN), Paraguay 2155, Ciudad Autónoma de Buenos Aires, CP1121, Argentina. Electronic address: somartin@campus.fm…
- Universidad de Buenos Aires, Facultad de Ciencias Médicas, Departamento de Biología Celular, Histología, Embriología y Genética, Paraguay 2155, Ciudad Autónoma de Buenos Aires, CP1121, Argentina. Electronic address: mbr…
- CONICET- Universidad de Buenos Aires, Instituto de Biología Celular y Neurociencias "Prof E. De Robertis" (IBCN), Paraguay 2155, Ciudad Autónoma de Buenos Aires, CP1121, Argentina; Universidad de Buenos Aires, Facultad…
Förderung
- Fund for Scientific and Technological Research
- Universidad de Buenos Aires
- Secretaria de Ciencia y Tecnica, Universidad de Buenos Aires
- Agencia Nacional de Promoción Científica y Tecnológica
- National Agency for the Promotion of Research Technological Development and Innovation
- National Scientific and Technical Research Council
Zitieren
APA
Buján, S., Miret, N., Torres, D., Pontillo, C., Chiappini, F., Nicola Candia, A., Leguizamón, M., Martín Mena, S., Bressan, M., Scicolone, G., Candolfi, M., & Randi, A. (2026). Aryl hydrocarbon receptor activation by imidacloprid as a promoter of HER2(+) breast cancer progression: In silico, in vitro and in vivo studies. Environmental Research. https://doi.org/10.1016/j.envres.2026.125482
Vancouver
Buján S, Miret N, Torres D, Pontillo C, Chiappini F, Nicola Candia A, et al. Aryl hydrocarbon receptor activation by imidacloprid as a promoter of HER2(+) breast cancer progression: In silico, in vitro and in vivo studies. Environmental Research. 2026. doi:10.1016/j.envres.2026.125482
BibTeX
@article{Bujn2026,
author = {Buján, Sol and Miret, Noelia and Torres, Dimas and Pontillo, Carolina and Chiappini, Florencia and Nicola Candia, Alejandro and Leguizamón, MaríaAgustina and Martín Mena, Sofia and Bressan, Melisa and Scicolone, Gabriel and Candolfi, Marianela and Randi, Andrea},
title = {Aryl hydrocarbon receptor activation by imidacloprid as a promoter of HER2(+) breast cancer progression: In silico, in vitro and in vivo studies},
journal = {Environmental Research},
year = {2026},
doi = {10.1016/j.envres.2026.125482}
}
EUVIMED